Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
Beth Israel Deaconess Medical Center
Eli Lilly and Company
Pheast Therapeutics
Tango Therapeutics, Inc.
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Pliant Therapeutics, Inc.
Cogent Biosciences, Inc.
Eli Lilly and Company
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Seoul National University Hospital
Merck Sharp & Dohme LLC
Tango Therapeutics, Inc.
Instituto do Cancer do Estado de São Paulo
Kestrel Therapeutics, Inc.
Astellas Pharma Inc
InnoPharmax Inc.
Novartis
National Cancer Institute (NCI)
Thomas Jefferson University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Virogin Biotech Ltd.
J-Pharma Co., Ltd.
National Cancer Institute (NCI)
Hoosier Cancer Research Network
Sichuan Cancer Hospital and Research Institute
Sir Run Run Shaw Hospital
Assistance Publique - Hôpitaux de Paris
Taiho Oncology, Inc.
University Hospital, Angers
Hutchmed
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
Jazz Pharmaceuticals
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Rigel Pharmaceuticals
Arbele Limited
Alentis Therapeutics AG
University Hospital, Bordeaux
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City of Hope Medical Center
University Hospital, Angers
M.D. Anderson Cancer Center
West China Hospital
Hoffmann-La Roche